IMNM Biotechnology · Oncology · Clinical stage · Pre-revenue · Thesis updated July 2, 2026

Varegacestat now carries Immunome's near-term story

Immunome has no product sales yet and reported no collaboration revenue in the first quarter of 2026.
The lead drug, varegacestat, moved from clinical trial risk to FDA review risk after an April 2026 NDA submission.
The Phase 3 RINGSIDE trial cut the risk of disease progression or death by 84% versus placebo in topline results.
Cash was $582.7 million at March 31, 2026, but the company still expects to need more funding over time.
The biggest open question is whether varegacestat can win approval and compete with OGSIVEO, an approved drug.

01 Running thesis

A cleaner lead story, still not a business

Immunome made real progress. It submitted the FDA approval application, called an NDA, for varegacestat in April 2026. It also started the first Phase 1 site for IM-3050 in March 2026 and got FDA clearance to begin human testing for IM-1617 in April 2026. That is strong execution for a company whose value depends almost fully on future drugs.

The bull case is now easier to state. Varegacestat has positive Phase 3 topline data in desmoid tumors, including an 84% reduction in the risk of disease progression or death versus placebo and a confirmed response rate of 56% versus 9% for placebo. If the FDA accepts and approves the application, Immunome could move toward its first commercial launch.

The bear case did not go away. Immunome has not received FDA approval for any product. It also has to sell into a market where OGSIVEO is already approved for desmoid tumors. Even with $582.7 million of cash at March 31, 2026, the company expects losses to continue and says it will need more financing to support operations and commercialization if varegacestat is approved.

The next year is mostly about proof. Watch for FDA acceptance of the NDA, a PDUFA date if the filing is accepted, the start of the IM-1617 Phase 1 trial, initial IM-1021 lymphoma data, and IND submissions for IM-1340 and IM-1335.

May 2026▲Immunome submitted the varegacestat NDA, started the first IM-3050 Phase 1 site, and received IND clearance for IM-1617. Cash was $582.7 million at March 31, 2026.

Mar 2026▲Positive Phase 3 topline data for varegacestat moved the lead asset from trial risk toward regulatory risk. The company also reported a runway of at least 12 months from the 10-K filing date.

Nov 2025→IM-3050's Phase 1 start moved from the second half of 2025 to early 2026 because of third-party supply issues. The main varegacestat data catalyst stayed on track.

Aug 2025▼The AbbVie collaboration ended in July 2025, removing a source of collaboration revenue. That made future funding more dependent on capital markets.

May 2025▲IM-3050 received IND clearance in April 2025, adding another clinical-stage asset. The lead thesis still centered on the upcoming varegacestat Phase 3 data.

Mar 2025▲IM-1021 entered Phase 1 and IM-3050 moved toward the clinic, broadening the pipeline beyond varegacestat. The company also disclosed more preclinical ADC work.

Nov 2024→The initial view framed Immunome as a clinical-stage oncology biotech with one lead Phase 3 asset, early ADC and RLT programs, heavy cash burn, and direct competition in desmoid tumors.

02 Business model

No sales, funded by investors

Immunome does not make money from selling drugs today. Its AbbVie collaboration ended in July 2025, and no further collaboration revenue will be recognized under that agreement. In the first quarter of 2026, collaboration revenue was zero.

The company spends cash to move drug candidates through lab work, human trials, FDA filings, and launch preparation. In the first quarter of 2026, research and development expense was $46.4 million, total operating expense was $59.3 million, and net loss was $53.8 million.

Funding comes mainly from stock sales. Immunome had $582.7 million in cash and cash equivalents at March 31, 2026, and management said this should fund planned operations for at least 12 months from the May 2026 filing date. That does not mean the company is fully funded through a mature launch or through all pipeline trials.

The model works only if at least one drug becomes valuable enough to pay for years of losses. Until then, shareholders carry dilution risk, meaning future stock sales could reduce each current share's claim on the company.

03 Product portfolio

One late drug, several early shots

Growth engine

Varegacestat

Varegacestat is an oral gamma secretase inhibitor, a drug that blocks a cancer-linked signaling pathway. It has positive Phase 3 topline data in desmoid tumors and an NDA was submitted to the FDA in April 2026.

Option

IM-1021

IM-1021 is a ROR1 antibody-drug conjugate, which is an antibody linked to a cancer-killing payload. It is in Phase 1 testing, with objective responses seen in B-cell lymphoma patients and initial lymphoma data planned for 2026.

Option

IM-3050

IM-3050 is a FAP-targeted radioligand therapy, which aims to deliver radiation to tumor-linked cells. Immunome initiated the first Phase 1 site in March 2026.

Option

IM-1617

IM-1617 is a first-in-class antibody-drug conjugate aimed at an undisclosed receptor found across several solid tumors. It received IND clearance in April 2026, and a Phase 1 trial was planned for the second quarter of 2026.

Option

IM-1340

IM-1340 is a preclinical solid tumor antibody-drug conjugate. Immunome expects to submit an IND in mid-2026.

Option

IM-1335

IM-1335 is another preclinical solid tumor antibody-drug conjugate. Its target overlaps with a discontinued competitor program, which makes the safety and design work important to watch.

04 Business segments

One segment, spending tells the story

Varegacestat R&D21%declining

IM-1021 R&D8%modest

IM-3050 R&D3%modest

IM-1617 R&D2%growing fast

Other direct R&D21%growing fast

Indirect R&D44%growing fast

Immunome reports one operating segment and had no product revenue in the first quarter of 2026. Because there is no revenue mix, the chart uses Q1 2026 research and development expense allocation by program, with indirect R&D shown separately.

05 Risk factors

What could break the case

FDA says no, delays, or narrows the label

High impact · Medium odds

Varegacestat is the main near-term value driver. The NDA was submitted in April 2026, but approval is not guaranteed. A refusal to file, a major delay, a request for more data, or a narrower label would hurt the launch case.

We watchFDA acceptance of the NDA, PDUFA date assignment, advisory committee plans, and the final label if approved.

OGSIVEO blocks the launch

High impact · Medium odds

Varegacestat would not enter an empty market. OGSIVEO is already approved for desmoid tumors, so doctors and patients may already have a standard option. Immunome needs the full RINGSIDE data and safety profile to show why its drug should be used.

We watchFull RINGSIDE presentation, physician feedback, payer coverage terms, and any early launch commentary if approval happens.

Cash burn forces dilution

Medium impact · High odds

Immunome had $582.7 million in cash at March 31, 2026, but it also had a $782.0 million accumulated deficit. Operating cash used in the first quarter of 2026 was $58.6 million. A full launch and several trials could require more stock sales, debt, or partnerships.

We watchQuarterly cash balance, operating cash use, ATM share sales, new equity offerings, debt deals, or partnership terms.

Early pipeline data disappoints

Medium impact · Medium odds

IM-1021, IM-3050, IM-1617, IM-1340, and IM-1335 are still early. Many cancer drugs fail between Phase 1 and approval. Weak safety, low response rates, or slow enrollment would reduce the value of Immunome's broader platform.

We watchInitial IM-1021 lymphoma data in 2026, IM-1617 Phase 1 start, IM-3050 enrollment, and IND updates for IM-1340 and IM-1335.

Third parties slow the work

Medium impact · Medium odds

Immunome relies on outside groups for manufacturing, supply, and clinical trial work. That already mattered when IM-3050 was delayed because of third-party diagnostic radiotracer supply. Similar problems could delay trials or launch readiness.

We watchTrial start delays, supply updates, manufacturing readiness comments, and changes in expected timelines.

06 Quick answers

In one breath

Does Immunome have revenue?

Not from product sales. Its AbbVie collaboration ended in July 2025, and the company reported no collaboration revenue in the first quarter of 2026.

What is Immunome's most important drug?

Varegacestat is the lead asset. It has positive Phase 3 topline results in desmoid tumors and an FDA approval application was submitted in April 2026.

What is an ADC?

An antibody-drug conjugate is a targeted cancer drug. It uses an antibody to find cells with a certain marker, then delivers a toxic payload meant to kill those cells.

What should investors watch next?

The biggest item is FDA acceptance and timing for the varegacestat NDA. Investors should also watch IM-1021 data, IM-1617 trial initiation, and IND submissions for IM-1340 and IM-1335.